Predictors of hypogammaglobulinemia during rituximab maintenance therapy in rheumatoid arthritis: A 12-year longitudinal multi-center study

Rituximab (RTX) is an anti-CD20 monoclonal antibody that selectively depletes B-cell population. Thus, it presents a potential risk for the development of hypogammaglobulinemia and related infectious events. Our aim was to identify predictors of hypogammaglobulinemia in RA patients long-term treated with RTX.

Source: Seminars in Arthritis and Rheumatism - February 20, 2018 Category: Rheumatology Authors: G. Boleto, J. Avouac, J. Wipff, M. Forien, M. Dougados, C. Roux, A. Kahan, P. Dieude, Y. Allanore Source Type: research